Europe Opioid Use Disorder Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Formulation, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$959.5 MnPlaceholder estimate
Estimate 2025$1.00 Bn18.6% of the global market
Projected 2034$1.50 Bn 49.9%Adds $500.8 Mn over 9 forecast years
CAGR 2025–20344.6%Faster than 22% of 186 Pharmaceuticals markets here
Key players5Companies profiled
Europe is 18.61% of the global market.
Among regions, the largest is North America at $2.99 Bn.
5 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Opioid Use Disorder Drugs Market Analysis Executive Summary
Opioid use disorder drugs such as buprenorphine, methadone and naltrexone reduce cravings and overdose risk.
Key segments of the opioid Use Disorder Drugs market include drug (Buprenorphine, Methadone and Naltrexone) and formulation (Sublingual, Extended-Release Injectable and Implants).
Europe Opioid Use Disorder Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Opioid Use Disorder Drugs Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the opioid Use Disorder Drugs market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the opioid Use Disorder Drugs market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the opioid Use Disorder Drugs market.
Competitive Landscape for Opioid Use Disorder Drugs Market in Europe
The opioid Use Disorder Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Opioid Use Disorder Drugs Market in Europe
Opioid Use Disorder Drugs in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], CBG-MEB (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15] ClinicalTrials.gov lists 5 studies on Opioid Use Disorder Drugs that are recruiting, active or about to start in Europe.[16]
[16]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for opioid Use Disorder Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Formulation
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Indivior
7.2 Alkermes
7.3 Orexo
7.4 Braeburn
7.5 Emergent BioSolutions
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The opioid Use Disorder Drugs market can be segmented based on various criteria, including drug, formulation and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Opioid Use Disorder Drugs right now, from free public sources.
Clinical trials
5 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia
Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Opioid Use Disorder Drugs market in Europe?
Placeholder estimate: about $1.00 Bn in 2025, rising to about $1.50 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Opioid Use Disorder Drugs market in Europe growing?
Placeholder estimate: about 4.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Opioid Use Disorder Drugs market report cover?
The report splits the market by drug (Buprenorphine, Methadone, Naltrexone, Naloxone), formulation (Sublingual, Extended-Release Injectable, Implants, Nasal Spray) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Opioid Use Disorder Drugs market?
Key players include Indivior, Alkermes, Orexo, Braeburn and Emergent BioSolutions.
What is driving the Opioid Use Disorder Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the opioid Use Disorder Drugs market. Governments and employers are investing more in mental health care.
Who regulates Opioid Use Disorder Drugs in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Opioid Use Disorder Drugs are running in Europe?
5 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Opioid Use Disorder Drugs?
PubMed lists 7,232 papers on Opioid Use Disorder Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.